Mellicell, Inc.
Watertown, MA
- UEI
- EFGLLLKFX2S7
- CAGE
- 8N0Q3
- Primary NAICS
- Not on record
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 17 Union St, Watertown, MA 02472, USA
- Website
- mellicell.com
- Founded
- 2020
- Employees
- 1-10
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Similar vendors
About the company
Mellicell, Inc., a for-profit biotechnology company based in Watertown, Massachusetts, receives federal research funding as a grant recipient under the NSF Small Business Innovation Research (SBIR) program and the National Institutes of Health (NIH), focusing on development of engineered human cell technologies for drug discovery and development. The vendor operates as a prime recipient only (100% of recent awards); all work is grant-funded, with no federal contract prime or IDV positions.
Mellicell's core capability centers on proprietary cell engineering and automation platforms — specifically, the M3 platform — designed to generate mature, functional human cells at scale for pharmaceutical industry drug efficacy testing and mechanism-of-action studies. The vendor has received three federal grants totaling $1.8 million obligated since January 2024. NSF has funded two awards under the Technology, Innovation, and Partnerships program (CFDA 47.084): a $275,000 SBIR Phase I project awarded January 15, 2024 (completed September 30, 2024) to develop automation and protocols for mature human fat cell generation from adult stem cells, and a $1.25 million SBIR Phase II Cooperative Agreement awarded August 1, 2026 (performance through July 31, 2028) to scale the technology and develop novel automation devices for drug development applications. The National Institute of Diabetes and Digestive and Kidney Diseases (NIH) awarded a Project Grant of unspecified amount on May 9, 2024 (completion April 30, 2027) for development of adipocyte engineering technology to model obesity-related fat cell dysfunction; this work includes collaboration with Brigham and Women's Hospital to validate the M3 platform against ex vivo mature fat cells. All three awards explicitly note no planned subawards.
Mellicell serves two customer agencies — NSF (two awards) and NIDDK (one award) — with 100% coverage of the visible award portfolio. Two awards face ultimate completion in the next twenty-four months, creating potential recompete activity. Performance occurs at Mellicell's Watertown, Massachusetts facility with no field sites noted.
Quick answers
Is Mellicell, Inc. registered in SAM.gov?
Yes. Mellicell, Inc.'s SAM.gov registration is active through December 9, 2026.
What is Mellicell, Inc.'s most recent federal award?
Mellicell, Inc.'s most recent federal grant award is Sbir phase II: industrial-scale technology for drug development (2538072), from National Science Foundation, on August 1, 2026.
On GovTribe
See Mellicell, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors